{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:08:55Z","timestamp":1784167735294,"version":"3.55.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11102-024-01477-x","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T04:42:52Z","timestamp":1735533772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of acromegaly-induced diabetes: an updated proposal"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-9618","authenticated-orcid":false,"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":false,"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-023-03339-1","volume":"81","author":"M Moustaki","year":"2023","unstructured":"Moustaki M, Paschou SA, Xekouki P et al (2023) Secondary diabetes mellitus in acromegaly. Endocrine 81:1\u201315. https:\/\/doi.org\/10.1007\/s12020-023-03339-1","journal-title":"Endocrine"},{"key":"1477_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-00993-x","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-024-00993-x","journal-title":"Nat Rev Endocrinol"},{"key":"1477_CR3","doi-asserted-by":"publisher","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","volume":"33","author":"L Maione","year":"2019","unstructured":"Maione L, Chanson P (2019) National acromegaly registries. Best Pract Res Clin Endocrinol Metab 33:101264. https:\/\/doi.org\/10.1016\/j.beem.2019.02.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1477_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01092-6","author":"B Biagetti","year":"2020","unstructured":"Biagetti B, Aulinas A, Casteras A et al (2020) HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary. https:\/\/doi.org\/10.1007\/s11102-020-01092-6","journal-title":"Pituitary"},{"key":"1477_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01415-x","author":"E Pascual-Corrales","year":"2024","unstructured":"Pascual-Corrales E, Biagetti B, Marazuela M et al (2024) Glucose metabolism outcomes after pituitary surgery in patients with acromegaly. Pituitary. https:\/\/doi.org\/10.1007\/s11102-024-01415-x","journal-title":"Pituitary"},{"key":"1477_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T, Lindberg A, van der Jan A et al (2019) Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63:563\u2013572. https:\/\/doi.org\/10.1007\/s12020-018-1792-0","journal-title":"Endocrine"},{"key":"1477_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","volume":"25","author":"R Salvatori","year":"2022","unstructured":"Salvatori R, Maffei P, Webb SM et al (2022) Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience. Pituitary 25:420\u2013432. https:\/\/doi.org\/10.1007\/s11102-022-01206-2","journal-title":"Pituitary"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"Esposito D, Olsson DS, Franz\u00e9n S et al (2022) Effect of diabetes on morbidity and mortality in patients with acromegaly. J Clin Endocrinol Metab 107:2483\u20132492. https:\/\/doi.org\/10.1210\/clinem\/dgac400","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00157-8","author":"R Taylor","year":"2024","unstructured":"Taylor R (2024) Understanding the cause of type 2 diabetes. Lancet Diabetes Endocrinol S. https:\/\/doi.org\/10.1016\/S2213-8587(24)00157-8. 2213-8587(24)00157\u20138","journal-title":"Lancet Diabetes Endocrinol S"},{"key":"1477_CR10","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","volume":"159","author":"C-J Chen","year":"2017","unstructured":"Chen C-J, Ironside N, Pomeraniec IJ et al (2017) Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir (Wien) 159:2193\u20132207. https:\/\/doi.org\/10.1007\/s00701-017-3318-6","journal-title":"Acta Neurochir (Wien)"},{"key":"1477_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3171\/2017.2.JNS162673","volume":"129","author":"JP Almeida","year":"2018","unstructured":"Almeida JP, Ruiz-Trevi\u00f1o AS, Liang B et al (2018) Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature. J Neurosurg 129:404\u2013416. https:\/\/doi.org\/10.3171\/2017.2.JNS162673","journal-title":"J Neurosurg"},{"key":"1477_CR12","doi-asserted-by":"publisher","first-page":"e220349","DOI":"10.1530\/EC-22-0349","volume":"12","author":"AH Zamanipoor Najafabadi","year":"2023","unstructured":"Zamanipoor Najafabadi AH, van der Meulen M, Priego Zurita AL et al (2023) Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine conditions (Endo-ERN): results from a meta-analysis and survey study. Endocr Connect 12:e220349. https:\/\/doi.org\/10.1530\/EC-22-0349","journal-title":"Endocr Connect"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1055\/s-0031-1275703","volume":"43","author":"H-S Chen","year":"2011","unstructured":"Chen H-S, Wu T-E, Jap T-S et al (2011) Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery. Horm Metab Res 43:433\u2013439. https:\/\/doi.org\/10.1055\/s-0031-1275703","journal-title":"Horm Metab Res"},{"key":"1477_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1477_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53:210\u2013219. https:\/\/doi.org\/10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"key":"1477_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/cen.13285","volume":"86","author":"PJ Caron","year":"2017","unstructured":"Caron PJ, Petersenn S, Houchard A et al (2017) Glucose and lipid levels with lanreotide autogel 120\u00a0mg in treatment-na\u00efve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf) 86:541\u2013551. https:\/\/doi.org\/10.1111\/cen.13285","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JOL (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152\u2013177. https:\/\/doi.org\/10.1210\/er.2008-0027","journal-title":"Endocr Rev"},{"key":"1477_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000371818","volume":"103","author":"NC Olarescu","year":"2016","unstructured":"Olarescu NC, Heck A, Godang K et al (2016) The metabolic risk in patients newly diagnosed with acromegaly is related to Fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 103:197\u2013206. https:\/\/doi.org\/10.1159\/000371818","journal-title":"Neuroendocrinology"},{"key":"1477_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","volume":"16","author":"JJ Kopchick","year":"2020","unstructured":"Kopchick JJ, Berryman DE, Puri V et al (2020) The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nat Rev Endocrinol 16:135\u2013146. https:\/\/doi.org\/10.1038\/s41574-019-0280-9","journal-title":"Nat Rev Endocrinol"},{"key":"1477_CR21","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2007-2780","volume":"93","author":"PU Freda","year":"2008","unstructured":"Freda PU, Shen W, Heymsfield SB et al (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334\u20132343. https:\/\/doi.org\/10.1210\/jc.2007-2780","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR22","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1073\/pnas.0705408104","volume":"104","author":"KF Petersen","year":"2007","unstructured":"Petersen KF, Dufour S, Savage DB et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104:12587\u201312594. https:\/\/doi.org\/10.1073\/pnas.0705408104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1477_CR23","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.2337\/db12-0206","volume":"61","author":"C Flannery","year":"2012","unstructured":"Flannery C, Dufour S, Rab\u00f8l R et al (2012) Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 61:2711\u20132717. https:\/\/doi.org\/10.2337\/db12-0206","journal-title":"Diabetes"},{"key":"1477_CR24","doi-asserted-by":"publisher","first-page":"101501","DOI":"10.1016\/j.aohep.2024.101501","volume":"29","author":"F Barrera","year":"2024","unstructured":"Barrera F, Uribe J, Olvares N et al (2024) The Janus of a disease: diabetes and metabolic dysfunction-associated fatty liver disease. Ann Hepatol 29:101501. https:\/\/doi.org\/10.1016\/j.aohep.2024.101501","journal-title":"Ann Hepatol"},{"key":"1477_CR25","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1210\/en.2005-1494","volume":"147","author":"E Karaskov","year":"2006","unstructured":"Karaskov E, Scott C, Zhang L et al (2006) Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic \u03b2-Cell apoptosis. Endocrinology 147:3398\u20133407. https:\/\/doi.org\/10.1210\/en.2005-1494","journal-title":"Endocrinology"},{"key":"1477_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41598-022-25428-3","volume":"13","author":"H-E Choi","year":"2023","unstructured":"Choi H-E, Kim DY, Choi MJ et al (2023) Tranilast protects pancreatic \u03b2-cells from palmitic acid-induced lipotoxicity via FoxO-1 inhibition. Sci Rep 13:101. https:\/\/doi.org\/10.1038\/s41598-022-25428-3","journal-title":"Sci Rep"},{"key":"1477_CR27","doi-asserted-by":"publisher","unstructured":"Biagetti B, Sim\u00f3 R (2021) GH\/IGF-1 abnormalities and muscle impairment: from Basic Research to Clinical Practice. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22010415","DOI":"10.3390\/ijms22010415"},{"key":"1477_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygcen.2017.07.028","volume":"258","author":"HE Bergan-Roller","year":"2018","unstructured":"Bergan-Roller HE, Sheridan MA (2018) The growth hormone signaling system: insights into coordinating the anabolic and catabolic actions of growth hormone. Gen Comp Endocrinol 258:119\u2013133. https:\/\/doi.org\/10.1016\/j.ygcen.2017.07.028","journal-title":"Gen Comp Endocrinol"},{"key":"1477_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877\u2013884. https:\/\/doi.org\/10.1530\/EJE-10-1050","journal-title":"Eur J Endocrinol"},{"key":"1477_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","volume":"14","author":"AL Espinosa-de-los-Monteros","year":"2011","unstructured":"Espinosa-de-los-Monteros AL, Gonz\u00e1lez B, Vargas G et al (2011) Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14:231\u2013235. https:\/\/doi.org\/10.1007\/s11102-010-0284-x","journal-title":"Pituitary"},{"key":"1477_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferra\u00f9","year":"2018","unstructured":"Ferra\u00f9 F, Albani A, Ciresi A et al (2018) Diabetes secondary to Acromegaly: Physiopathology, clinical features and effects of Treatment. Front Endocrinol (Lausanne) 9:358. https:\/\/doi.org\/10.3389\/fendo.2018.00358","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1477_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09928-3","author":"B Biagetti","year":"2024","unstructured":"Biagetti B, Araujo-Castro M, Tebe C et al (2024) Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-024-09928-3","journal-title":"Rev Endocr Metab Disord"},{"key":"1477_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M et al (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549\u2013555. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00986.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1477_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1210\/jc.2008-1546","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M et al (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94:528\u2013537. https:\/\/doi.org\/10.1210\/jc.2008-1546","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/EJE-10-1096","volume":"164","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Fujii H, Takeshita A et al (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic \u03b2-cell function is preserved. Eur J Endocrinol 164:467\u2013473. https:\/\/doi.org\/10.1530\/EJE-10-1096","journal-title":"Eur J Endocrinol"},{"key":"1477_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0035-1569277","volume":"48","author":"C Jonas","year":"2016","unstructured":"Jonas C, Maiter D, Alexopoulou O (2016) Evolution of glucose tolerance after treatment of Acromegaly: a study in 57 patients. Horm Metab Res 48:299\u2013305. https:\/\/doi.org\/10.1055\/s-0035-1569277","journal-title":"Horm Metab Res"},{"key":"1477_CR37","doi-asserted-by":"publisher","unstructured":"Niculescu DA, Dusceac R, Caragheorgheopol A et al (2019) Disposition Index in active acromegaly. Front Endocrinol 10. https:\/\/doi.org\/10.3389\/fendo.2019.00637","DOI":"10.3389\/fendo.2019.00637"},{"key":"1477_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11102-024-01386-z","volume":"27","author":"LG Zaifu","year":"2024","unstructured":"Zaifu LG, Niculescu DA, Kremer AE et al (2024) Glucose intolerance in acromegaly is driven by low insulin secretion; results from an intravenous glucose tolerance test. Pituitary 27:178\u2013186. https:\/\/doi.org\/10.1007\/s11102-024-01386-z","journal-title":"Pituitary"},{"key":"1477_CR39","doi-asserted-by":"publisher","first-page":"e240043","DOI":"10.1530\/ERC-24-0043","volume":"31","author":"M Araujo-Castro","year":"2024","unstructured":"Araujo-Castro M, Biagetti B, Men\u00e9ndez Torre E et al (2024) Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer 31:e240043. https:\/\/doi.org\/10.1530\/ERC-24-0043","journal-title":"Endocr Relat Cancer"},{"key":"1477_CR40","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I et al (2019) Pegvisomant improves glucose metabolism in Acromegaly: a Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104:2892\u20132902. https:\/\/doi.org\/10.1210\/jc.2018-02281","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR41","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc24-SREV","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) Summary of revisions: standards of Care in Diabetes\u20142024. Diabetes Care 47:S5\u2013S10. https:\/\/doi.org\/10.2337\/dc24-SREV","journal-title":"Diabetes Care"},{"key":"1477_CR42","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.2337\/dc24-S008","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) 8. Obesity and Weight Management for the Prevention and Treatment of type 2 diabetes: standards of Care in Diabetes\u20132024. Diabetes Care 47:S145\u2013S157. https:\/\/doi.org\/10.2337\/dc24-S008","journal-title":"Diabetes Care"},{"key":"1477_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-21-0900","volume":"186","author":"P Wolf","year":"2022","unstructured":"Wolf P, Salenave S, Durand E et al (2022) Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. Eur J Endocrinol 186:173\u2013181. https:\/\/doi.org\/10.1530\/EJE-21-0900","journal-title":"Eur J Endocrinol"},{"key":"1477_CR44","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577\u20131585. https:\/\/doi.org\/10.1007\/s00125-017-4342-z","journal-title":"Diabetologia"},{"key":"1477_CR45","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1096\/fj.201800529RR","volume":"33","author":"Z Polianskyte-Prause","year":"2019","unstructured":"Polianskyte-Prause Z, Tolvanen TA, Lindfors S et al (2019) Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB J 33:2858\u20132869. https:\/\/doi.org\/10.1096\/fj.201800529RR","journal-title":"FASEB J"},{"key":"1477_CR46","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae477","author":"H-H Wang","year":"2024","unstructured":"Wang H-H, Lin S-H, Hung S-Y et al (2024) Renal protective effect of Metformin in type 2 diabetes patients. J Clin Endocrinol Metabolism. https:\/\/doi.org\/10.1210\/clinem\/dgae477. dgae477","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1477_CR47","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz M, Guigas B, Bertrand L et al (2014) Metformin: from mechanisms of action to therapies. Cell Metabol 20:953\u2013966. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018","journal-title":"Cell Metabol"},{"key":"1477_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000531432","volume":"148","author":"JZ Li","year":"2023","unstructured":"Li JZ, Li YR (2023) Cardiovascular Protection by Metformin: latest advances in Basic and Clinical Research. Cardiology 148:374\u2013384. https:\/\/doi.org\/10.1159\/000531432","journal-title":"Cardiology"},{"key":"1477_CR49","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","author":"A Giustina","year":"2019","unstructured":"Giustina A, Barkan A, Beckers A et al (2019) A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/2042098614523031","volume":"5","author":"T Karagiannis","year":"2014","unstructured":"Karagiannis T, Boura P, Tsapas A (2014) Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Adv Drug Saf 5:138. https:\/\/doi.org\/10.1177\/2042098614523031","journal-title":"Therapeutic Adv Drug Saf"},{"key":"1477_CR51","first-page":"509","volume":"35","author":"R Pathak","year":"2010","unstructured":"Pathak R, Bridgeman MB (2010) Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the management of diabetes. Pharm Ther 35:509","journal-title":"Pharm Ther"},{"key":"1477_CR52","first-page":"223","volume":"12","author":"P Rai","year":"2019","unstructured":"Rai P, Dwibedi N, Rowneki M et al (2019) Dipeptidyl Peptidase-4 inhibitors and Joint Pain: a retrospective cohort study of older veterans with type 2 diabetes Mellitus. Am Health Drug Benefits 12:223\u2013231","journal-title":"Am Health Drug Benefits"},{"key":"1477_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4183\/aeb.2018.473","volume":"14","author":"ZA Sayiner","year":"2018","unstructured":"Sayiner ZA, Okyar B, K\u0131sac\u0131k B, DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS\/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY (2018) Acta Endocrinol (Buchar) 14:473\u2013476. https:\/\/doi.org\/10.4183\/aeb.2018.473","journal-title":"Acta Endocrinol (Buchar)"},{"key":"1477_CR54","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.rcsop.2021.100022","volume":"2","author":"T Park","year":"2021","unstructured":"Park T, Bresnahan M, Griggs SK et al (2021) Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: a retrospective cohort study. Explor Res Clin Soc Pharm 2:100022. https:\/\/doi.org\/10.1016\/j.rcsop.2021.100022","journal-title":"Explor Res Clin Soc Pharm"},{"key":"1477_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","volume":"213","author":"C Luna-Marco","year":"2024","unstructured":"Luna-Marco C, Iannantuoni F, Hermo-Argibay A et al (2024) Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radic Biol Med 213:19\u201335. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.01.015","journal-title":"Free Radic Biol Med"},{"key":"1477_CR56","doi-asserted-by":"publisher","unstructured":"Jensen MH, Gasbjerg LS, Skov-Jeppesen K et al (2024) GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly. J Clin Endocrinol Metab dgae 583. https:\/\/doi.org\/10.1210\/clinem\/dgae583","DOI":"10.1210\/clinem\/dgae583"},{"key":"1477_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2012","unstructured":"Meloni AR, DeYoung MB, Lowe C, Parkes DG (2012) GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metab 15:15. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01663.x","journal-title":"Diabetes Obes Metab"},{"key":"1477_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9:1\u201329. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Sig Transduct Target Ther"},{"key":"1477_CR59","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W et al (2015) Adipose tissue redistribution and ectopic lipid deposition in active Acromegaly and effects of Surgical Treatment. J Clin Endocrinol Metab 100:2946\u20132955. https:\/\/doi.org\/10.1210\/jc.2015-1917","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR60","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2017-01210","volume":"102","author":"MA Bredella","year":"2017","unstructured":"Bredella MA, Schorr M, Dichtel LE et al (2017) Body composition and ectopic lipid changes with biochemical control of Acromegaly. J Clin Endocrinol Metab 102:4218\u20134225. https:\/\/doi.org\/10.1210\/jc.2017-01210","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR61","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/EJE-16-1047","volume":"177","author":"MH Aguiar-Oliveira","year":"2017","unstructured":"Aguiar-Oliveira MH, Souza AHO, Oliveira CRP et al (2017) MECHANISMS IN ENDOCRINOLOGY: the multiple facets of GHRH\/GH\/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. Eur J Endocrinol 177:R85\u2013R97. https:\/\/doi.org\/10.1530\/EJE-16-1047","journal-title":"Eur J Endocrinol"},{"key":"1477_CR62","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/acel.12188","volume":"13","author":"Z Gong","year":"2014","unstructured":"Gong Z, Kennedy O, Sun H et al (2014) Reductions in serum IGF-1 during aging impair health span. Aging Cell 13:408\u2013418. https:\/\/doi.org\/10.1111\/acel.12188","journal-title":"Aging Cell"},{"key":"1477_CR63","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","volume":"166","author":"I Salcedo","year":"2012","unstructured":"Salcedo I, Tweedie D, Li Y, Greig NH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 166:1586. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01971.x","journal-title":"Br J Pharmacol"},{"key":"1477_CR64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41574-018-0020-6","volume":"14","author":"P Rorsman","year":"2018","unstructured":"Rorsman P, Huising MO (2018) The somatostatin-secreting pancreatic \u03b4-cell in health and disease. Nat Rev Endocrinol 14:404\u2013414. https:\/\/doi.org\/10.1038\/s41574-018-0020-6","journal-title":"Nat Rev Endocrinol"},{"key":"1477_CR65","doi-asserted-by":"publisher","unstructured":"Jepsen SL, Albrechtsen NJW, Windel\u00f8v JA et al (2021) Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R\u2013dependent manner. https:\/\/doi.org\/10.1172\/jci.insight.143228. JCI Insight 6:","DOI":"10.1172\/jci.insight.143228"},{"key":"1477_CR66","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24:887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"key":"1477_CR67","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s13300-023-01381-w","volume":"14","author":"K Heinla","year":"2023","unstructured":"Heinla K, Vasar E, Reppo I et al (2023) GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers. Diabetes Therapy 14:777. https:\/\/doi.org\/10.1007\/s13300-023-01381-w","journal-title":"Diabetes Therapy"},{"key":"1477_CR68","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M K\u00f6rner","year":"2007","unstructured":"K\u00f6rner M, St\u00f6ckli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736\u2013743. https:\/\/doi.org\/10.2967\/jnumed.106.038679","journal-title":"J Nucl Med"},{"key":"1477_CR69","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1210\/jc.2018-01504","volume":"104","author":"M Hage","year":"2019","unstructured":"Hage M, Chalign\u00e9 R, Viengchareun S et al (2019) Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative Somatotropinomas. J Clin Endocrinol Metab 104:1777\u20131787. https:\/\/doi.org\/10.1210\/jc.2018-01504","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR70","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3390\/cells11233846","volume":"11","author":"J Rymuza","year":"2022","unstructured":"Rymuza J, Kober P, Rusetska N et al (2022) Transcriptomic classification of Pituitary neuroendocrine tumors causing acromegaly. Cells 11:3846. https:\/\/doi.org\/10.3390\/cells11233846","journal-title":"Cells"},{"key":"1477_CR71","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2024. Diabetes Care 47:S158\u2013S178. https:\/\/doi.org\/10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"1477_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20517\/jca.2022.42","volume":"3","author":"B Werbner","year":"2023","unstructured":"Werbner B, Tavakoli-Rouzbehani OM, Fatahian AN, Boudina S (2023) The dynamic interplay between cardiac mitochondrial health and myocardial structural remodeling in metabolic heart disease, aging, and heart failure. J Cardiovasc Aging 3:9. https:\/\/doi.org\/10.20517\/jca.2022.42","journal-title":"J Cardiovasc Aging"},{"key":"1477_CR73","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.3390\/ijms25147711","volume":"25","author":"LN Ionic\u0103","year":"2024","unstructured":"Ionic\u0103 LN, Lin\u021ba AV, B\u0103tr\u00een AD et al (2024) The off-target cardioprotective mechanisms of sodium\u2013glucose cotransporter 2 inhibitors: an overview. Int J Mol Sci 25:7711. https:\/\/doi.org\/10.3390\/ijms25147711","journal-title":"Int J Mol Sci"},{"key":"1477_CR74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.diabet.2014.02.008","volume":"41","author":"C Owen","year":"2015","unstructured":"Owen C, Lees EK, Mody N, Delibegovi\u0107 M (2015) Regulation of growth hormone induced JAK2 and mTOR signalling by hepatic protein tyrosine phosphatase 1B. Diabetes Metab 41:95\u2013101. https:\/\/doi.org\/10.1016\/j.diabet.2014.02.008","journal-title":"Diabetes Metab"},{"key":"1477_CR75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M (2020) SGLT2 inhibitors produce Cardiorenal benefits by promoting Adaptive Cellular Reprogramming to induce a state of Fasting Mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508\u2013511. https:\/\/doi.org\/10.2337\/dci19-0074","journal-title":"Diabetes Care"},{"key":"1477_CR76","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Critical reanalysis of the mechanisms underlying the Cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient Deprivation Signaling\/Autophagy hypothesis. Circulation 146:1383\u20131405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732","journal-title":"Circulation"},{"key":"1477_CR77","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"-GallegoCG Santos","year":"2021","unstructured":"Santos -GallegoCG, Requena -IbanezJ, Antonio, San AR et al (2021) Empagliflozin ameliorates diastolic dysfunction and left ventricular Fibrosis\/Stiffness in nondiabetic heart failure. JACC: Cardiovasc Imaging 14:393\u2013407. https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.042","journal-title":"JACC: Cardiovasc Imaging"},{"key":"1477_CR78","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of Cardiovascular benefits of Sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC: Basic Translational Sci 5:632. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004","journal-title":"JACC: Basic Translational Sci"},{"key":"1477_CR79","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.hfc.2019.03.001","volume":"15","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Di Somma C, Pivonello R (2019) Acromegaly and heart failure. Heart Fail Clin 15:399\u2013408. https:\/\/doi.org\/10.1016\/j.hfc.2019.03.001","journal-title":"Heart Fail Clin"},{"key":"1477_CR80","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1681\/ASN.2018010103","volume":"29","author":"C Wanner","year":"2018","unstructured":"Wanner C, Heerspink HJL, Zinman B et al (2018) Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 29:2755\u20132769. https:\/\/doi.org\/10.1681\/ASN.2018010103","journal-title":"J Am Soc Nephrol"},{"key":"1477_CR81","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"1477_CR82","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","volume":"108","author":"B Biagetti","year":"2023","unstructured":"Biagetti B, Iglesias P, Villar-Taibo R et al (2023) Mortality in Acromegaly diagnosed in older individuals in Spain is higher in women compared to the General Spanish Population. J Clin Endocrinol Metab 108:2193\u20132202. https:\/\/doi.org\/10.1210\/clinem\/dgad141","journal-title":"J Clin Endocrinol Metab"},{"key":"1477_CR83","doi-asserted-by":"publisher","first-page":"70","DOI":"10.17161\/kjm.vol15.15881","volume":"15","author":"F Delgado","year":"2022","unstructured":"Delgado F, Valverde A, Vaca RG (2022) Diabetic Ketoacidosis in undiagnosed acromegaly: a Case Report and Literature Review. Kans J Med 15:70. https:\/\/doi.org\/10.17161\/kjm.vol15.15881","journal-title":"Kans J Med"},{"key":"1477_CR84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","volume":"73","author":"A Zaina","year":"2021","unstructured":"Zaina A, Grober Y, Abid A et al (2021) Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review. Endocrine 73:65\u201370. https:\/\/doi.org\/10.1007\/s12020-021-02718-w","journal-title":"Endocrine"},{"key":"1477_CR85","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/dme.12159","volume":"30","author":"AG Jones","year":"2013","unstructured":"Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30:803. https:\/\/doi.org\/10.1111\/dme.12159","journal-title":"Diabet Med"},{"key":"1477_CR86","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S2213-8587(15)00204-1","volume":"3","author":"J Hine","year":"2015","unstructured":"Hine J, Paterson H, Abrol E et al (2015) SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 3:503\u2013504. https:\/\/doi.org\/10.1016\/S2213-8587(15)00204-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1477_CR87","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1111\/dom.14785","volume":"24","author":"E Maddaloni","year":"2022","unstructured":"Maddaloni E, Bolli GB, Frier BM et al (2022) C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes Metabolism 24:1912\u20131926. https:\/\/doi.org\/10.1111\/dom.14785","journal-title":"Diabetes Obes Metabolism"},{"key":"1477_CR88","doi-asserted-by":"publisher","first-page":"170","DOI":"10.14740\/jem.v0i0.892","volume":"13","author":"H Yanai","year":"2023","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H (2023) The Safety of Sodium Glucose Cotransporter 2 inhibitors for the Elderly Diabetic patients. J Endocrinol Metabolism 13:170\u2013173. https:\/\/doi.org\/10.14740\/jem.v0i0.892","journal-title":"J Endocrinol Metabolism"},{"key":"1477_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tem.2018.11.007","volume":"30","author":"Z Adnan","year":"2019","unstructured":"Adnan Z (2019) Sodium glucose co-transporter inhibitors in patients with acromegaly and diabetes. Trends Endocrinol Metabolism 30:77\u201379. https:\/\/doi.org\/10.1016\/j.tem.2018.11.007","journal-title":"Trends Endocrinol Metabolism"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01477-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01477-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01477-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T14:32:55Z","timestamp":1741444375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01477-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01477-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"26 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BB, MA, MM and MP-D have received consulting fees, research support, or participated in clinical trials supported by Pfizer, Ipsen, and Recordati.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"\u201cNot applicable\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"\u201cNot applicable\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"15"}}